SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2020 to be approximately $51 million. Read the full press release >

SAN DIEGO, November 30, 2020 – SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in the first quarter of 2021. Read the press release >

We come to work every day to do something extraordinary that can make a difference in the lives of the patients we serve. This is the core of who we are at Travere Therapeutics.